The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review

Table 4

Standard mean difference and event rates.

Group	Outcome	Standard mean difference/event rates		Number of studies
		Mean	95% CI
Conbercept	Polyp regression rate	0.683	0.552 to 0.790	3
	BCVA	0.305	0.097 to 0.513	4
	CRT	1.083	0.690 to 1.476	4
	Injection frequency	5.533	4.789 to 6.276	4
	Adverse events	0.026	0.003 to 0.175	5
Ranibizumab	Polyp regression rate	0.324	0.276 to 0.376	6
	BCVA	0.274	0.127 to 0.421	9
	CRT	0.819	0.688 to 0.950	5
	Injection frequency	5.030	4.267 to 5.793	4
	Adverse events	0.040	0.023 to 0.068	12
Aflibercept	Polyp regression rate	0.496	0.411 to 0.582	11
	BCVA	0.673	0.380 to 0.966	13
	CRT	1.435	1.098 to 1.772	15
	Injection frequency	6.811	6.176 to 7.445	5
	Adverse events	0.042	0.022 to 0.077	10